GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Ucap Cloud Information Technology Co.,Ltd
688228
5
Yangtze Optical Electronic
688143
US Stock MarketDetailed Quotes
CTXR Citius Pharmaceuticals
- 3.3000
- +0.1500+4.76%
Close Jan 24 16:00 ET
- 3.2800
- -0.0200-0.61%
Post 19:09 ET
28.36MMarket Cap-0.55P/E (TTM)
3.4000High3.0200Low165.49KVolume3.0200Open3.1500Pre Close543.05KTurnover2.11%Turnover RatioLossP/E (Static)8.59MShares26.750052wk High0.40P/B25.87MFloat Cap2.440052wk Low--Dividend TTM7.84MShs Float750.0000Historical High--Div YieldTTM12.06%Amplitude2.4400Historical Low3.2810Avg Price1Lot Size
Trending Stocks
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day
Citius Pharmaceuticals Stock Forum
Citius Pharmaceuticals Advances LYMPHIR Launch Plans for Breakthrough CTCL Treatment
PR Newswire· 4 mins ago
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...
The engagement of Jefferies as a financial advisor is a strategically significant move that could reshape Citius Oncology's future. Jefferies' strong track record in healthcare M&A and their expertise in orchestrating deals averaging $500M-$2B in the biotech sector positions them well to explore value-maximizing opportunities. With LYMPHIR™ recently FDA-approved and ready for commercialization, the timing aligns perfectly with...
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Monday, 6th January at 7:50 am
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategi...
Citius Pharmaceuticals Inc - Regains Compliance With Nasdaq Listing Rule 5550(a)(2)
might pull from this, let's see tonight!
No comment yet